LUKAS
路迦生醫股份有限公司
LUKAS is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is ATL administration (Phase 2; recruiting, Hepatocellular Carcinoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ATL administration | — | Phase 2; recruiting | Hepatocellular Carcinoma | Taiwan | 2026-09-01 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.